ArticleScience advances2018
CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 74 citations in OpenAlex.
- Macrophage RSAD2 Couples mtDNA Synthesis With a Self-Amplifying Inflammatory Circuit to Orchestrate Tissue Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biological functions and clinical implications of the CMPK2 across multisystemic diseases.Cell & bioscience · 2025Review
- Complexity of the neutrophil transcriptome in early and severe rheumatoid arthritis: a role for microRNAs?Journal of leukocyte biology · 2025Article
- Host restriction factors against porcine epidemic diarrhea virus: a mini-review.Veterinary research · 2025Review
- Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy.Current cancer drug targets · 2025Article
- Interferons in HIV-1 infection: mechanisms, antiviral potentials, and therapeutic challenges.Frontiers in immunology · 2025Review
- CMPK2 Promotes CD4Cell biochemistry and biophysics · 2024Article
- Three Arabidopsis UMP kinases have different roles in pyrimidine nucleotide biosynthesis and (deoxy)CMP salvage.The Plant cell · 2024Article
- Transcriptional Signatures of Domestication Revealed through Meta-Analysis of Pig, Chicken, Wild Boar, and Red Junglefowl Gene Expression Data.Animals : an open access journal from MDPI · 2024Article
- Article
- Potential risk genes for primary Sjogren's syndrome from a meta-analysis by linear regression and random forest classification.Genes & diseases · 2024Article
- MiR-155 Negatively Regulates Anti-Viral Innate Responses among HIV-Infected Progressors.Viruses · 2023Article
- Several cell-intrinsic effectors drive type I interferon-mediated restriction of HIV-1 in primary CD4Cell reports · 2023Article
- BCL-G: 20 years of research on a non-typical protein from the BCL-2 family.Cell death and differentiation · 2023Review
- Article
- CMPK2 restricts Zika virus replication by inhibiting viral translation.PLoS pathogens · 2023Article
- Change in Long Non-Coding RNA Expression Profile Related to the Antagonistic Effect ofCurrent issues in molecular biology · 2023Article
- CMPK2 is a host restriction factor that inhibits infection of multiple coronaviruses in a cell-intrinsic manner.PLoS biology · 2023Article
- Several cell-intrinsic effectors drive type I interferon-mediated restriction of HIV-1 in primary CD4bioRxiv : the preprint server for biology · 2023Article
- Multi-OMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Ramy El-DiwanyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-3224-6414
Mary SolimanDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-4765-4442
Sho SugawaraDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-5187-423X
Florian BreitwieserCenter for Computational Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-6192-0853
Alyza SkaistDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Candelaria CoggianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0003-3297-8057
Neel SangalDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Michael ChattergoonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-2220-1116
Justin R BaileyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Joel N BlanksonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-9683-8021
Stuart C RayDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-1051-7260
Sarah J WheelanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-9002-0800
David L ThomasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Ashwin BalagopalDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-6143-3104
Johns Hopkins University · USHoward Hughes Medical Institute · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MVaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MTraining Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7MThe Progression of Hepatitis C Among IDUs with HIVR01DA016078 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BALAGOPAL, ASHWIN, THOMAS, DAVID L · 2002 to 2016
$10.9MComputational Methods for Genome Assembly, Transcript Assembly, and Variant DiscoveryR01HG006677 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI SALZBERG, STEVEN L. · 2011 to 2025
$10.7MThe Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV EliminationR01DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI IRVIN, RISHA, THOMAS, DAVID L · 2000 to 2024
$8.7MSpatial Models of Intrahepatic Hepatitis C Virus Propagation in HumansR01AI116868 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI ASHWIN BALAGOPAL, Ruy M Ribeiro · 2016 to 2026
$8.5MHIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0MInstitute for Clinical and Translational ResearchUL1TR000424 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2012 to 2012
$6.0MRecognition of HIV by the Inflammasome Signaling ComplexK08AI102696 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHATTERGOON, MICHAEL ANAND · 2013 to 2017
$937kNCATS NIH HHS UL1 TR000424NCI NIH HHS P30 CA006973NHGRI NIH HHS R01 HG006677NIAID NIH HHS K08 AI102696NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI116868NIDA NIH HHS R01 DA013806NIDA NIH HHS R01 DA016078NIDA NIH HHS R37 DA013806NIGMS NIH HHS T32 GM008752
Abstract
Type 1 interferons (IFN) are critical for host control of HIV and simian immunodeficiency virus. However, it is unknown which of the hundreds of interferon-stimulated genes (ISGs) restrict HIV in vivo. We sequenced RNA from cells that support HIV replication (activated CD4
Indexed as
Antiviral AgentsCD4-Positive T-LymphocytesGene Expression RegulationHIVHIV InfectionsHumansInterferon-alphaInterferon alpha-2Interferon Regulatory FactorsProspective StudiesProto-Oncogene Proteins c-bcl-2Virus ReplicationAntiviral AgentsBCL2L14 protein, humanInterferon-alphaInterferon alpha-2Interferon-alpha2bInterferon Regulatory FactorsProto-Oncogene Proteins c-bcl-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.